Related Experiment Video

Updated: Apr 17, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.3K

Hypoglycemic activity of curcumin synthetic analogues in alloxan-induced diabetic rats

Kusal K Das1, Nima Razzaghi-Asl2,3, Swati N Tikare4

  • 1a Department of Physiology, Shri. B.M. Patil Medical College , BLDE University , Bijapur , Karnataka , India .

Journal of Enzyme Inhibition and Medicinal Chemistry
|February 17, 2015
PubMed

Insights

New synthetic curcumin analogues show promise as oral antidiabetic agents. Compound 4 demonstrated significant in vitro and in vivo hypoglycemic effects, potentially offering a safer alternative for type 2 diabetes management.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Endocrinology

Background:

  • Current type 2 diabetes therapies often fail to achieve normoglycemia due to drug limitations or side effects.
  • There is a need for novel, potent, and safe oral antidiabetic agents.

Purpose of the Study:

  • To evaluate the in vitro and in vivo hypoglycemic effects of synthetic polyphenolic curcumin analogues.
  • To identify potential lead compounds for oral antidiabetic drug development.

Main Methods:

  • In vitro screening of 10 synthetic curcumin analogues for hypoglycemic activity.
  • In vivo assessment using alloxan-induced diabetic male albino rats.
  • Oral glucose tolerance test (OGTT) and structure-activity relationship (SAR) analysis.

Main Results:

  • 7-bis(3,4-dimethoxyphenyl)hepta-1,6-diene-3,5-dione (compound 4) exhibited the most potent in vitro hypoglycemic activity.
  • Compound 4 showed comparable in vivo glucose-lowering effects to glipizide in OGTT.
  • Structure-activity relationship analysis provided insights into the antidiabetic potential of the analogues.

Conclusions:

  • Compound 4 is a promising candidate for an oral hypoglycemic agent.
  • Further research into compound 4 could lead to new treatments for type 2 diabetes.
  • Synthetic curcumin analogues offer a viable avenue for developing safer antidiabetic drugs.
Keywords:
CurcuminOGTTdiabetic ratshypoglycemicin vitrosynthesis

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.2K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.7K

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
914
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
996
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
994
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K